Towards Healthcare

Regenerative Medicine Companies and Corporate Growth

Date : 11 November 2025

Uncover the Leaders Shaping the Future of Regenerative Medicine Market

Regenerative Medicine Market Companies

Market Growth

The global regenerative medicine market is projected to reach USD 139.70 billion by 2034, growing from USD 24.39 billion in 2025, at a CAGR of 21.4% during the forecast period from 2025 to 2034, as a result of the rising demand for cell and gene therapies.

Regenerative Medicine Market Size 2023 - 2034

  • In April 2025, at the Global Life Science Hub in Tokyo, an inaugural Taiwan-Japan Investment and Industry Networking Event was conducted. For exploring the market growth, cross-border investment, and technology collaboration, the leading pharmaceutical and biotech companies were brought together by this event. To combine the biotech strengths of Taiwan and clinical development capabilities, along with investment from Japan, the importance of collaboration for regenerative medicine and drug innovation was highlighted by key organizations like FIRM, LINK-J, BPIPO, and DCB.
  • In February 2025, a grant of $4M USD was awarded to Entos Pharmaceuticals, which is a clinical-stage genetic medicines company, by the California Institute for Regenerative Medicine (CIRM). For the development of ENTLEP001, which is a durable genetic medicine developed for the treatment of congenital generalized lipodystrophy (CGL), as well as to support the completion of IND-enabling activities, this fund will be used.

Competitive Landscape

The regenerative medicine market is dynamic, with key players driving innovation and growth. Companies like Medtronic, Thermo Fischer Scientific and Novartis are prominent, focusing on stem cell therapies, tissue engineering, and gene therapies. Startups such as Bluebird Bio and CRISPR Therapeutics contribute to the competitive landscape, emphasizing gene editing advancement. Collaboration between pharmaceutical giants and biotech firms and increasing research initiatives shape the evolving competitive scenario in regenerative medicine.

Latest Announcement by Industry Leaders

In August 2025, the Chairperson of ReGen 2025, Founder Director of Orthobiologix Clinic, and Consultant Orthopedic Surgeon & Regenerative Medicine Specialist, Dr. Sharmila Tulpule, stated that they were honoured to host ReGen 2025, which brought the brightest minds in regenerative medicine from India and across the world together. To amplify the research, policy alignment, and clinical adoption, conferences similar to this play an important role, as regenerative medicine is evolving rapidly, driving the evolution in healthcare. Thus, a dynamic platform was provided for hands-on learning, global collaboration, and knowledge exchange by ReGen 2025. To shape the future of biologic therapies in India, innovation showcase, research sessions, tissue engineering to live workshops, and keynote lectures on gene editing will be offered in this ReGen 2025.

Martin Ridderstråle, Senior Vice President and Head of Medical Science at Novo Nordisk Foundation, in an interview, shared that the company is focusing on regenerative medicines, especially cell therapies, due to its increased demand and huge developments in Denmark. In the future, the company will find new opportunities in other areas of regenerative medicine. He also shared that AI will speed up the analysis of large amounts of data and improve manufacturing practices.

Recent Developments in the Regenerative Medicine Market

  • In September 2024, UC Merced received a $5.4 million grant from the California Institute for Regenerative Medicine to support research in vascular models and human stem cells.
  • In June 2024, Minaris Regenerative Medicine GmBH adopted the newest version of Werum PAS-X MES by Korber to convert its production management to digital processes. The digital process will result in faster batch release, and time and cost savings.
  • In May 2024, researchers from the Icahn School of Medicine at Mount Sinai developed a regenerative medicine therapy for treating diabetic wounds. The therapy included tiny fat molecules loaded with genetic instructions to reduce inflammation.

Partner with our experts to explore the Regenerative Medicine Market at sales@towardshealthcare.com